Oral semaglutide in a tablet intended for treatment of adults with type 2 diabetes. Credit: Novo Nordisk A/S.

Novo Nordisk has reported positive results from the Phase IIIb SUSTAIN 9 clinical trial evaluating Ozempic (semaglutide) when added to an SGLT-2 inhibitor (SGLT-2i) in adults living with type 2 diabetes.

Ozempic is a once-weekly human glucagon-like peptide-1 (GLP-1) analogue intended to be used as an adjunct to diet and exercise for improving glycaemic control in type 2 diabetes patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial met its primary endpoint with a statistically significant and superior reduction of 1.5% in HbA1c, compared to 0.1% with placebo, both given in combination with SGLT2-i therapy.

A secondary endpoint analysis revealed statistically significant and superior decrease in body weight of 4.7kg, which was found to be 0.9kg in placebo group.

“The results from SUSTAIN 9 demonstrated that Ozempic in combination with an SGLT-2 inhibitor is effective in lowering blood sugar and reducing body weight.”

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: “The results from SUSTAIN 9 demonstrated that Ozempic in combination with an SGLT-2 inhibitor is effective in lowering blood sugar and reducing body weight.

“These data further reinforce the results from across the SUSTAIN clinical development programme and the benefits of Ozempic that clinicians from many countries are already seeing in their day-to-day practices.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The double-blind, randomised, parallel-group SUSTAIN 9 trial evaluated the safety and efficacy of 1mg Ozempic with SGLT-2i therapy, as monotherapy or in combination with metformin or sulfonylurea, over 30 weeks.

Primary outcome of the Phase IIIb study was a change in HbA1c from baseline at week 30.

SUSTAIN 9 is part of Ozempic’s SUSTAIN clinical development programme involving ten Phase III trials, including a cardiovascular outcomes study in type 2 diabetes patients with high cardiovascular risk.